Trial Outcomes & Findings for The Effect of Growth Hormone Replacement on Liver Fat (NCT NCT00774579)

NCT ID: NCT00774579

Last Updated: 2019-07-12

Results Overview

IHCL content determined by proton magnetic resonance spectroscopy (1H MRS).

Recruitment status

COMPLETED

Target enrollment

30 participants

Primary outcome timeframe

6 months

Results posted on

2019-07-12

Participant Flow

Between April 2008 and April 2009 adult hypopituitary patients with untreated GHD were identified and recruited at the endocrine clinics of Imperial College Healthcare NHS Trust.

Participant milestones

Participant milestones
Measure
GH Replacement
Patients with growth hormone (GH) deficiency starting GH replacement.
Control
Patients with growth hormone (GH) deficiency not starting GH replacement.
Overall Study
STARTED
9
9
Overall Study
COMPLETED
9
9
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

The Effect of Growth Hormone Replacement on Liver Fat

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
GH Replacement
n=9 Participants
Patients with growth hormone (GH) deficiency starting GH replacement.
Control
n=9 Participants
Patients with growth hormone (GH) deficiency not starting GH replacement.
Total
n=18 Participants
Total of all reporting groups
Age, Continuous
53 years
STANDARD_DEVIATION 8 • n=99 Participants
52 years
STANDARD_DEVIATION 9 • n=107 Participants
52 years
STANDARD_DEVIATION 9 • n=206 Participants
Sex: Female, Male
Female
7 Participants
n=99 Participants
7 Participants
n=107 Participants
14 Participants
n=206 Participants
Sex: Female, Male
Male
2 Participants
n=99 Participants
2 Participants
n=107 Participants
4 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
9 Participants
n=99 Participants
9 Participants
n=107 Participants
18 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Region of Enrollment
United Kingdom
9 participants
n=99 Participants
9 participants
n=107 Participants
18 participants
n=206 Participants

PRIMARY outcome

Timeframe: 6 months

IHCL content determined by proton magnetic resonance spectroscopy (1H MRS).

Outcome measures

Outcome measures
Measure
GH Replacement
n=9 Participants
Patients with growth hormone (GH) deficiency starting GH replacement.
Control
n=9 Participants
Patients with growth hormone (GH) deficiency not starting GH replacement.
Intrahepatocellular Lipid (IHCL) Content
-0.63 % change from baseline
Standard Deviation 4.53
0.11 % change from baseline
Standard Deviation 1.46

SECONDARY outcome

Timeframe: 6 months

total adipose tissue assessed by MRI scan

Outcome measures

Outcome measures
Measure
GH Replacement
n=9 Participants
Patients with growth hormone (GH) deficiency starting GH replacement.
Control
n=9 Participants
Patients with growth hormone (GH) deficiency not starting GH replacement.
Total Adipose Tissue
-1.8 kg
Standard Deviation 3.2
0.24 kg
Standard Deviation 2.28

Adverse Events

GH Replacement

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Control

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Prof. Desmond Johnston

Imperial College Healthcare London

Phone: 020 3312 1253

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place